Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ENANTA PHARMACEUTICALS INC.

Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)
Listen to this Section


$11.40
-0.3350 ( -2.86% ) 38.8K

Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Clinical Trial Pipeline Stages


Drug Name Stage
MAVYRET (Glecaprevir)DetailsHCV (Hepatitis C Virus) Approved
Zelicapavir /EDP-938 (N protein-inhibitor)DetailsViral infection, Respiratory syncytial virus, Respiratory virus Phase 2
EDP-235DetailsViral infection, COVID-19 Phase 2
EDP-514 (HBV Core inhibitor)DetailsHepatitis B Phase 2
EDP-323DetailsRespiratory virus, Respiratory syncytial virus, Viral infection Phase 2a
EDP-305 (FXR Agonist)DetailsNon-alcoholic steatohepatitis Failed
ENP-297 (FXR inhibitor)DetailsNon-alcoholic steatohepatitis Failed

Market Data


Open $11.40
Previous Close $11.73
Volume 38.8K
Market Cap $326.84M
Day Range $11.32 - $11.75
52 Week Range $6.44 - $17.15
Shares Outstanding 29.08M
Change % -2.86%
Net Change ▼ -0.3350
Insider Ownership -0.08%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2013
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -1,101,978.00

Date Type Amount Purchased Purchaser
2024-08-09 Sale -1467.00 Rottinghaus Scott T.
2024-07-15 Sale -4299.00 Rottinghaus Scott T.
2024-06-17 Sale -7266.00 Kieffer Tara Lynn
2024-05-01 Sale -150000.00 Kowalsky Matthew Paul
2024-03-08 Sale -15700.00 Peterson Kristine
2024-03-08 Sale -15700.00 Russell Lesley
2024-03-08 Sale -15700.00 Hata Yujiro S
2024-03-08 Sale -15700.00 Vance Terry
2024-03-08 Sale -15700.00 CARTER BRUCE L A
2024-03-08 Sale -15700.00 FOLETTA MARK G

SEC Filings


Form Type Description Pages Date
schedule Other 2 Nov 13, 2025
schedule Other 1 Nov 07, 2025
schedule Other 1 Oct 09, 2025
8-k 8K-related 15 Oct 01, 2025
8-k 8K-related 14 Sep 29, 2025
8-k 8K-related 37 Sep 29, 2025
3 Insider transactions 2 Sep 08, 2025
3 Insider transactions 2 Sep 08, 2025
8-k 8K-related 10 Aug 27, 2025
8-k 8K-related 12 Aug 20, 2025

Latest News


× Before browsing our site, please accept our cookies policy